

10/30/00
JC772 U.S. PTOPlease type a plus sign (+) inside this box - +

PTO/SB/05 (1/98)

Approved for use through 09/30/2000 OMB 0651-0032
Patent and Trademark Office, U S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>		Attorney Docket No. 746200-000062
First Inventor or Application Identifier Jérôme AUCOUTURIER		
Title NOVEL VACCINE COMPOSITION AND USE OF SURFACTANTS AS ADJUVANTS OF IMMUNITY		
Express Mail Label No.		

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents		ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
<p>1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original, and a duplicate for fee processing)</i></p> <p>2. <input checked="" type="checkbox"/> Specification Total Pages [20] (preferred arrangement set forth below)</p> <ul style="list-style-type: none"> - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings <i>(if filed)</i> - Detailed Description - Claim(s) - Abstract of the Disclosure <p>3. <input type="checkbox"/> Drawing(s) (35 USC 113) Total Sheets []</p> <p>4. <input type="checkbox"/> Oath or Declaration Total Pages []</p> <ul style="list-style-type: none"> a <input type="checkbox"/> Newly executed (original or copy) b <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i> [Note Box 5 below] i <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b) <p>5. <input type="checkbox"/> Incorporation By Reference <i>(useable if Box 4b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein</p>		
<p>6. <input type="checkbox"/> Microfiche Computer Program <i>(Appendix)</i></p> <p>7. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i></p> <ul style="list-style-type: none"> a <input type="checkbox"/> Computer Readable Copy b <input type="checkbox"/> Paper Copy (identical to computer copy) c <input type="checkbox"/> Statement verifying identity of above copies 		

ACCOMPANYING APPLICATION PARTS

- 8. Assignment Papers (cover sheet & document(s))
- 9. 37 CFR 3.73(b) Statement Power of Attorney *(when there is an assignee)*
- 10. English Translation Document *(if applicable)*
- 11. Information Disclosure Statement Copies of IDS (IDS)/PTO-1449 Citations
- 12. Preliminary Amendment
- 13. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- 14. *Small Entity Statement filed in prior application, Statement(s) Status still proper and desired (PTO/SB/09-12)
- 15. Certified Copy of French Priority Document No. 99 13618 Filed October 29, 1999
- 16. Other

*A new statement is required to be entitled to pay small entity fees, except where one has been filed in a prior application and is being relied upon


17. If a **CONTINUING APPLICATION**, check appropriate box, and supply the requisite information below and in a preliminary amendment
 Continuation Divisional Continuation-in-part (CIP) of prior application No. _____
 Prior application information: Examiner: _____ Group/Art Unit: _____

18. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number or Bar Code Label	Customer No 22204	or <input type="checkbox"/> Correspondence address below <i>(Insert Customer No. or Attach bar code label here)</i>
---	-------------------	--

Name: Robert M. Schulman	Firm: NIXON PEABODY LLP
Address: 8180 Greensboro Drive, Suite 800	City: McLean State VA
Country: U.S.A. Telephone (703) 790-9110	Zip Code 22102 FAX (703) 883-0370

Name (Print/Type)	Robert M. Schulman	Registration No. (Attorney Agent) 31,196
-------------------	--------------------	--

Signature		Date: October 30, 2000
-----------	---	------------------------

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231
F:\DATA\wp2\CLIENTS\6200\0062\Docs\Appln Transmittal.wpd

JC930 U.S. PTO
09/698121

10/30/00

APPLICATION FOR U.S. LETTERS PATENT

for:

**NOVEL VACCINE COMPOSITION AND USE OF SURFACTANTS AS
ADJUVANTS OF IMMUNITY**

by:

**Jérôme AUCOUTURIER
Vincent GANNE and
Gérard TROUVE**

**NIXON PEABODY LLP
8180 Greensboro Drive, Suite 800
McLean, Virginia 22102
Telephone (703) 790-9110**

Attorney Docket No. 746200-0062

CROSS-REFERENCE TO RELATED APPLICATION

The present application claims the benefit under 35 U.S.C. §119 of FR 99 13618 filed in France on October 29, 1999, the disclosure of which is hereby incorporated by reference.

5

BACKGROUND OF THE INVENTION:

(i) Field of the Invention

The present invention relates to novel adjuvants for vaccine compositions, and to compositions comprising at least one antigen, in particular an antigen of viral, bacterial or parasitic origin, and at least one adjuvant.

(ii) Description of the Related Art

The development of inactivated vaccines or vaccines containing purified antigens is increasingly significant, since it makes it possible to avoid adverse side effects. However, the improvement in the quality of the antigens occurs to the detriment of their immunogenic nature. It is for this reason that they are combined with adjuvants of immunity.

Adjuvants of immunity are products which increase the reactions of the immune system, when they are administered in the presence of antigens of viral, bacterial or synthetic origin. They cause a massive appearance of macrophages at the site of injection, and then in the lymph nodes, increase the production of specific immunoglobulins, antibodies, and stimulate many cells involved in immune defense mechanism.

These adjuvants are diverse in nature. They can, for example, consist of liposomes or emulsions.

Very effective Freund's adjuvants: they result from the combination of a mineral oil and of a mannitol ester, possibly containing a killed mycobacterium. Vaccines prepared by mixing in equal parts a Freund's adjuvant with an aqueous antigenic medium are still used as standards throughout the world for laboratory studies. They are in the form of water in oil (W/O) emulsions, i.e., emulsions in which the continuous phase is the oil. These emulsions are very viscous; they are thus difficult to inject ; they are also relatively unstable, since phase displacements

10
09
08
07
06
05
04
03
02
01
00
15
14
13
12
11
10
09
08
07
06
05
04
03
02
01
00

20

25

30

are observed only a few days after their preparation.

By way of ordinary adjuvants, there are also metal salts, such as aluminum hydroxide, cerium nitrate, zinc sulphate, colloidal iron hydroxide or calcium chloride.

Of these, aluminum hydroxide is the most commonly used. These adjuvants are described in the article by Rajesh K. Gupta et al., "Adjuvants, balance between toxicity and adjuvanticity" Vaccine, Vol. 11, Issue 3, 1993, pages 993-1006. They exhibit, however, weak immunostimulatory effectiveness, and sometimes induce, when these therapeutic compositions are injected, the formation of lesions and other local reactions, such as granulomas, at the point of injection.

More recently, it has been discovered that water-soluble salts of divalent or trivalent metals are good adjuvants of immunity, in particular manganese gluconate, calcium gluconate, manganese glycerophosphate, soluble aluminum acetate and aluminum salicylate. Such adjuvants are described in the international patent applications published under the numbers WO 96/32964 and WO 98/17311.

As other adjuvants of immunity, in particular in the case of mucosal administration, mention may be made of the sympathomimetic compounds described in the international patent application published under the number WO 98/15288.

20 SUMMARY AND OBJECTS OF THE INVENTION:

In the course of research into the development of novel adjuvants, the applicant has discovered that some surfactants themselves exhibit immunostimulatory effectiveness, and that it is thus possible to prepare aqueous vaccine compositions essentially free of oily phase, comprising one or more of these agents as an immunostimulant.

It is for this reason that the subject of the present invention is a composition in the form of an aqueous solution comprising:

- (i) at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence, and
- 30 (ii) as an adjuvant of immunity, a surfactant, or a mixture of surfactants, having an overall HLB number of between 5 and 15.

The term "antigen" or the phrase "at least one in vivo generator of a

compound comprising an amino acid sequence" refers to either killed microorganisms, such as viruses, bacteria or parasites, or purified fractions of these microorganisms, or living microorganisms whose pathogenic power has been attenuated. As a virus which can constitute an antigen according to the present invention, mention may be made of rabies virus, herpes viruses, such as the virus of Aujeszky's disease, orthomixoviruses such as Influenzae, picornaviruses such as the virus of foot-and-mouth disease, or retroviruses such as HIVs. As microorganisms of the bacterial type which can constitute an antigen according to the present invention, mention may be made of *E coli*, and those of the *Pasteurella*, *Furunculosis*, *Vibriosis*, *Staphylococcus* and *Streptococcus* genera. As parasites, mention may be made of the *Trypanosoma*, *Plasmodium* and *Leishmania* genera. Mention may also be made of recombinant viruses, in particular nonenveloped viruses such as adenoviruses, the vaccinia virus, the canarypox virus, herpes viruses or baculoviruses. Reference is also made to a living nonenveloped viral recombinant vector, the genome of which contains, inserted preferably into a portion which is nonessential for the replication of the corresponding enveloped virus, a sequence encoding an antigenic subunit which induces synthesis of antibodies and/or a protective effect against the above-mentioned pathogenic enveloped virus or microorganism; these antigenic subunits can be, for example, a protein, a glycoprotein, a peptide or a fraction which is a peptide and/or which is protective against an infection with a living microorganism such as an enveloped virus, a bacterium or a parasite. The exogenous gene inserted into the microorganism can be, for example, derived from an HIV or Aujeszky virus.

Mention may be made in particular of a recombinant plasmid consisting of a nucleotide sequence, into which is inserted an exogenous nucleotide sequence originating from a pathogenic microorganism or virus. The aim of the latter nucleotide sequence is to allow the expression of a compound comprising an amino acid sequence, the aim of this compound itself being to trigger an immune reaction in a host organism.

The expression "in vivo generator of a compound comprising an amino acid sequence" refers to an entire biological product capable of expressing said compound in the host organism into which said in vivo generator has been

introduced. The compound comprising the amino acid sequence can be a protein, a peptide or a glycoprotein. These *in vivo* generators are generally obtained by methods derived from genetic engineering. More particularly, they can consist of living microorganisms, generally a virus, playing the role of recombinant vector, into which is inserted a nucleotide sequence, in particular an exogenous gene. These 5 compounds are known in themselves, and are used in particular as recombinant subunit vaccines. In this respect, reference may be made to the article by M. Eloit et al., *Journal of Virology* (1990) 71, 2925-2431, and to the international patent applications published under the numbers WO-A-91/00107 and WO-A-94/16681.

The *in vivo* generators according to the invention can also consist of a recombinant plasmid which comprises an exogenous nucleotide sequence, and which is capable of expressing, in a host organism, a compound comprising an amino acid sequence. Such recombinant plasmids and their method of administration to a host organism were described in 1990 by Lin et al., *Circulation* 82: 2217, 2221; Cox et al., *J. of Virol.*, Sept. 1993, 67, 9, 5665-5667, and in the international application published under the number WO 95/25542. Depending on the nature of the nucleotide sequence included in the *in vivo* generator, the compound comprising the amino acid sequence which is expressed within the host organism can:

(i) be an antigen, and enable the triggering of an immune reaction; (ii) have a 20 curative action with respect to a disease, essentially a disease of a functional nature, which has been triggered in the host organism. In this case, the *in vivo* generator enables gene therapy type treatment of the host.

By way of example, such a curative action can consist of synthesis by the *in vivo* generator of cytokines, such as interleukins, in particular interleukin-2. These 25 interleukins allow the triggering or the reinforcement of an immune reaction directed towards selective elimination of cancerous cells.

A composition according to the invention comprises an antigen concentration which depends on the nature of this antigen and on the nature of the individual treated. It is, however, particularly noteworthy that an adjuvant according to the 30 invention makes it possible to notably decrease the conventional antigen dose required. The suitable antigen concentration can be determined conventionally by persons skilled in the art. Generally, this dose is about 0.1 µg/cm³ to 1 g/cm³, more

generally between 1 µg/cm³ and 100 mg/cm³.

The concentration of said in vivo generator in the composition according to the invention depends, here again, in particular on the nature of said generator and of the host in which is administered. This concentration can be easily determined by persons skilled in the art, on the basis of routine experiment. By way of indication, it may, however, be specified that, when the in vivo generator is a recombinant microorganism, its concentration in the composition according to the invention can be between 10² and 10¹⁵ microorganisms/cm³, preferably between 10⁵ and 10¹² microorganisms/cm³. When the in vivo generator is a recombinant plasmid, its concentration in the composition according to the invention can be between 0.01 and 100 g/dm³.

For the purpose of the present invention, the HLB number is calculated using the formula $HLB = 20 (1 - I_s/I_a)$, in which I_s represents the saponification index and I_a represents the acid index of said surfactant or of said mixture of surfactants. These two indices, saponification and acid indices, are determined by methods described in the European Pharmacopoeia.

The main subject of the invention is a composition as defined above, in which the surfactant(s) is (are) chosen from modified fatty substances and, preferably, the surfactants(s) is (are) chosen from modified fatty substances having an overall HLB number of between 6 and 14.

The modified fatty substances used in the context of the present invention can be of mineral, plant or animal origin. As modified fatty substances of mineral origin there are oils of petroleum origin. As modified fatty substances of plant origin, there are modified plant oils, for example modified groundnut, olive, sesame, soya bean, wheatgerm, grapeseed, sunflower, castor, flax, corn, copra, palm, walnut, hazelnut or rapeseed oils. As modified fatty substances of animal origin, there are, for example, modified squalane, modified squalene, modified spermaceti oil or modified tallow oil.

The term "modified fatty substances" refers in particular to the alkoxylated derivatives of fatty substances, and more particularly the alkoxylated derivatives of oils or the alkoxylated derivatives of alkyl esters of oils, and more particularly the ethoxylated and/or propoxylated derivatives of oils or the ethoxylated and/or

propoxylated derivatives of the methyl, ethyl, linear or branched propyl, or linear or branched butyl esters of said oils. A subject of the invention is more specifically a composition as defined above, in which the modified fatty substance is chosen from the ethoxylated derivatives of oils having a number of EO's of between 1 and 60.

5 A subject of the invention is particularly a composition as defined above, in
which the modified fatty substance is an alkoxylated derivative of corn oil, or a
mixture of alkoxylated derivatives of corn oil, having an overall HLB number of
between 10 and 14, or a composition as defined above in which the modified fatty
substance is an ethoxylated derivative of castor oil, or a mixture of alkoxylated
10 derivatives of castor oil, having an overall HLB number of between 7 and 10. As
examples of such compositions, there is the composition in which the modified fatty
substance is chosen from the ethoxylated derivatives of corn oil having a number of
EO's of between 20 and 40, or the composition in which the modified fatty substance
is a mixture of ethoxylated derivatives of castor oil having a number of EO's equal to
15 7 and of ethoxylated derivatives of castor oil having a number of EO's equal to 60.

A composition which is a subject of the present invention contains between 0.2 mg/cm³ and 500 mg/cm³ of adjuvant, more particularly between 2 mg/cm³ and 500 mg/cm³ of adjuvant and preferably between 50 mg/cm³ and 200 mg/cm³ of adjuvant.

20 According to a second specific aspect of the present invention, a subject of
this invention is a composition as defined above, in which the surfactant(s) is (are)
chosen from the alkoxylated derivatives of esters of fatty acids and of polyols or the
alkoxylated derivatives of ethers of fatty alcohols and of polyols, and more
particularly from alkoxylated fatty acid triglycerides, the polyglycerol alkoxylated
25 esters of fatty acids, the alkoxylated esters of fatty acids with a hexol, such as for
example sorbitol or mannitol, or the alkoxylated esters of fatty acids with a hexol
anhydride, such as sorbitan or mannan.

30 As fatty acids which are suitable for preparing these modified esters, there
are more particularly those comprising from 12 to 22 carbon atoms, advantageously
a fatty acid which is liquid at 20 °C, such as for example those comprising from 16 to
18 carbon atoms, for instance oleic acid, ricinoleic acid or isostearic acid.

The composition as defined above contains in particular one or more

ethoxylated derivatives of esters of fatty acids and of polyols, or the ethoxylated derivatives of ethers of fatty alcohols and of polyols, having a number of EOs of between 1 and 60. The surfactant, or the mixture of surfactants, of this composition as defined above has more particularly an overall HLB number of between 10 and 14, and preferably between 12 and 13.. As an example of such a composition, there is the one in which the surfactant is an ethoxylated derivative of mannitan oleate having a number of Eos of between 5 and 15, and preferably between 7 and 11.

A surfactant according to the invention is preferably pharmaceutically acceptable for the mucous membranes; it must, in particular, be devoid of heavy metals and have very low acid or peroxide indices. It is also desirable for it to satisfy the standards of innocuity tests such as those described by S.S. Berlin, Annals of Allergy, 1962, 20, 473, or the abnormal toxicity tests described in the European Pharmacopoeia.

The composition according to the invention can comprise a conventional immunostimulant such as AVRIDINE®, N,N-dioctadecyl-N', N'-bis(2-hydroxyethyl)propanediamine, MDP (muramyl depeptide) derivatives, in particular threonyl-MDP, mycolic acid derivatives or Lipid A derivatives.

The composition according to the invention can comprises one or more water-soluble metal cation organic salts, such as for example calcium gluconate, manganese gluconate, aluminum salicylate or soluble aluminum acetate. When the adjuvant composition according to the invention comprises a pharmaceutically acceptable salt, this salt is at a concentration of 0.02 to 3000 mg/cm³, preferably 0.1 to 1000 mg/cm³, more preferably from 0.1 to 150 mg/cm³.

The composition according to the invention can comprise a sympathomimetic compound. The term "sympathomimetic compounds" refers in particular to amphetamines, catecholamines, phenylisopropylamines and tyramine. As examples of such compounds mention may be made in particular of isoproterenol, L-adrenalin, levarterenol, ephedrine, phenylephedrine and salbutamol When the adjuvant composition according to the invention comprises a sympathomimetic compound, this compound is at a concentration of 10⁻¹⁰ molar to 10⁻² molar, preferably from 10⁻⁷ molar to 10⁻⁵ molar.

The use of surfactants as defined above as adjuvants in the vaccine

compositions, and more particularly in the vaccine compositions which have no oily phase, constitutes another aspect of the present invention.

The composition according to the invention can be used as a preventive or curative medicinal product. Depending on the nature of the antigen or of the in vivo generator, a composition according to the invention can be administered to fish, crustaceans such as shrimps, poultry, in particular geese, turkeys, pigeons and chickens, to Canidae such as dogs, to Felidae such as cats, to pigs, to primates, to Bovidae, to Ovidae and to horses. The composition according to the invention can also be administered to humans. The administration of the composition can be carried out conventionally via the parenteral route, in particular by subcutaneous, intramuscular or intraperitoneal injection, or via the mucosal route, in particular orally, rectally, nasally or vaginally. According to another aspect of the invention, it consists of the use of an adjuvant as defined above for preparing a vaccine intended for preventing or for treating an infectious disease, in particular an infectious disease engendered by a virus or a microorganism, such as those mentioned above.

According to another final aspect of the present invention, it consists of the use of this adjuvant for preparing a composition intended to treat a disease of a functional nature, such as cancer or cystic fibrosis.

20

Example 1

100 microliters of various compositions containing a surfactant, phosphate buffer (PBS) and 10 mg/cm³ of ovalbumin were injected subcutaneously into various batches of 5 female mice of the OF1 strain, weighing an average of 18 to 20 grams, at t = 0 with a booster at t = 28 days.

25

Blood samples are taken at 14, 28, 42, 56, 90 and 180 days.

ELISA assays are carried out on the blood samples, for IgG1s in order to determine the humoral immune response, and IgG2as in order to determine the cellular immune response. Local reactions were evaluated at 7 days and at 35 days.

The compositions are as follows:

	Surfactant used (SA) (Composition) weight %	HLB of SA	SA in μl	Buffer (PBS) in μl	Antigen (10 mg/cm ³) in μl
5	Ethoxylated corn oil (3 EO _s) (Reference 1)	4.1	100	1900	20
10	Ethoxylated corn oil (10 EO _s) + glycerol at 2% of initial load (Composition A)	7.9	100	1900	20
15	Ethoxylated corn oil (20 EO _s) + glycerol at 2% of initial load (Composition B)	10.4	100	1900	20
20	Ethoxylated corn oil (30 EO _s) + glycerol at 2% of initial load (Composition C)	12.3	100	1900	20
25	Ethoxylated corn oil (40 EO _s) + glycerol at 2% of initial load (Composition D)	13.8	100	1900	20
30	Ethoxylated corn oil (20 EO _s) + glycerol at 4% of initial load (Composition E)	14.2	100	1900	20
35	Ethoxylated corn oil (40 EO _s) + glycerol at 4% of initial load (Composition F)	11.3	100	1900	20
	Mannitan oleate (5 EO _s) (Composition G)	10.9	100	1900	20
	Mannitan oleate (8 EO _s) (Composition H)	12.4	100	1900	20
	Mannitan oleate (10 EO _s) (Composition I)	13.1	100	1900	20
	Mannitan oleate (15 EO _s) (Composition J)	14.6	100	1900	20

	Surfactant Used (SA) (Composition) weight %	HLB of SA	SA in µl	Buffer (PBS) in µl	Antigen (10 mg/cm ³) in µl
5	Mannitan oleate (20 EO _s) (Composition K)	15.6	100	1900	20
	Mannitan oleate (40 EO _s) (Composition L)	17.3	100	1900	20
	Mannitan oleate (Reference 2)	3.3	100	1900	20
10	Mannitan oleate (8 EO _s) (Composition M)	12.1	100	1900	20
	Mannitan oleate + mannitan oleate (8 EO _s) (Composition N)	6.5	100	1900	20
15	Mannitan oleate + mannitan oleate (8 EO _s) (Composition O)	5.0	100	1900	20
	Manganese gluconate (Reference 3)	-	200	1800	20
20	Control	-	0	2000	20

The results of the ELISA assays are as follows:

Composition	IgG1 assay (timescale in days)					
	D14	D28	D42	D56	D90	D180
Reference (1)	1500	1000	32000	48000	32000	6000
Composition (A)	1000	1000	8000	12000	3000	1500
Composition (B)	1000	1000	64000	64000	16000	8000
Composition (C)	2000	1000	96000	128000	128000	12000
Composition (D)	1500	1000	6000	32000	64000	6000
Composition (E)	1000	1000	32000	64000	96000	24000
Composition (F)	3000	8000	64000	128000	128000	32000
Composition (G)	2000	2000	8000	64000	48000	8000
Composition (H)	4000	8000	128000	128000	48000	16000
Composition (I)	4000	1000	128000	96000	48000	12000
Composition (J)	1000	2000	64000	24000	6000	2000
Composition (K)	1000	1000	24000	12000	2000	2000
Composition (L)	1000	1000	18000	6000	2000	2000
	IgG1 assay (timescale in days)					

Composition	D14	D28	D42	D56	D90	D180
Reference (2)	1000	1000	32000	16000	3000	2000
Composition (M)	4000	4000	128000	128000	256000	48000
Composition (N)	1500	1000	128000	64000	32000	12000
Composition (O)	1000	1000	32000	20000	16000	2000
Reference (3)	32000	32000	256000	128000	32000	8000
Control	1000	1000	4000	2000	3000	1000

IgG2a assay (timescale in days)						
Composition	D14	D28	D42	D56	D90	D180
Reference (1)	1000	1000	1000	1500	3000	1000
Composition (A)	1000	1000	1000	1000	2000	1000
Composition (B)	1000	1000	2000	2000	2000	1000
Composition (C)	1000	1000	4000	1500	3000	1000
Composition (D)	1000	1000	1000	2000	4000	1000
Composition (E)	1000	1000	1000	2000	4000	1000
Composition (F)	1000	1000	1000	6000	4000	1000
Composition (G)	1000	1000	1000	8000	3000	100
Composition (H)	1000	1000	1000	3000	3000	1000
Composition (I)	1000	1000	4000	3000	2000	1000
Composition (J)	1000	1000	3000	1500	2000	1000
Composition (K)	1000	1000	1000	1500	2000	1000
Composition (L)	1000	1000	1000	1500	2000	1000
Reference (2)	1000	1000	1000	1500	3000	1000
Composition (M)	1000	1000	4000	1500	6000	1000
Composition (N)	1000	1000	4000	1500	2000	1000
Composition (O)	1000	1000	4000	1500	6000	1000
Reference (3)	1000	1000	4000	16000	2000	1000
Control	1000	1000	1000	1000	1000	1000

Example 2

The procedure is carried out in the same way as in Example 1, with the following ethoxylated castor oils as surfactants:

Surfactant used (SA) (Composition) weight %	HLB of SA	SA in µl	Buffer (PBS) in µl	Antigen (10 mg/cm³) in µl
Ethoxylated castor oil 100% (7 EO _s) (Composition P)	6	100	1900	20
Ethoxylated castor oil 89.13% (7 EO _s) + 10.87% (60EO _s) (Composition Q)	7	100	1900	20
Ethoxylated castor oil 78.26% (7 EO _s) + 21.74% (60EO _s) (Composition R)	8	100	1900	20
Ethoxylated castor oil 67.39% (7 EO _s) + 32.61% (60EO _s) (Composition S)	9	100	1900	20
Ethoxylated castor oil 56.52% (7 EO _s) + 43.487% (60 EO _s) (Composition T)	10	100	1900	20
Ethoxylated castor oil 50% (7 EO _s) + 50% (60 EO _s) (Composition U)	10.6	100	1900	20
Ethoxylated castor oil 45.65% (7 EO _s) + 54.35% (60 EO _s) (Composition V)	11	100	1900	20
Ethoxylated castor oil 34.78% (7 EO _s) + 65.22% (60 EO _s) (Composition W)	12	100	1900	20
Ethoxylated castor oil 23.91% (7 EO _s) + 76.09% (60 EO _s) (Composition X)	13	100	1900	20
Ethoxylated castor oil 13.04% (7 EO _s) + 86.96% (60 EO _s) (Composition Y)	14	100	1900	20
Mannitan oleate (15 EO _s) (Composition J)	14.6	100	1900	20

Surfactant used (SA) (Composition) weight %	HLB of SA	SA in µl	Buffer (PBS) in µl	Antigen (10 mg/cm³) in µl
Ethoxylated castor oil 100% (60EOs) (Composition Z)	15.2	100	1900	20
Control (C1)		1000	1000	20
Control (C2)		0	2000	20

10

The results of the ELISA assays are as follows:

	IgG1 assay (timescale in days)					
Composition	D14	D28	D42	D56	D90	D180
Composition (P)	1600	600	8000	16000	12000	nd
Composition (Q)	3200	600	16000	64000	48000	nd
Composition (R)	2400	400	48000	64000	64000	nd
Composition (S)	nd	nd	nd	nd	nd	nd
Composition (T)	600	100	16000	32000	32000	nd
Composition (U)	100	100	8000	32000	32000	nd
Composition (V)	100	100	8000	12000	6000	nd
Composition (W)	nd	nd	nd	nd	nd	nd
Composition (X)	200	100	3000	4000	3000	nd
Composition (Y)	400	100	4000	12000	8000	nd
Composition (Z)	100	100	8000	6000	6000	nd
Control (C1)	19200	12800	256000	128000	128000	nd
Control (C2)	100	100	4000	2000	1500	nd

25

	IgG2a assay (timescale in days)					
Composition	D14	D28	D42	D56	D90	D180
Composition (P)	100	100	8000	3000	3000	nd
Composition (Q)	100	100	1200	4000	8000	nd
Composition (R)	100	100	32000	8000	8000	nd
Composition (S)	nd	nd	nd	nd	nd	nd
Composition (T)	100	100	16000	3000	8000	nd
Composition (U)	100	100	6000	4000	4000	nd
Composition (V)	100	100	4000	15000	2000	nd
	IgG2a assay (timescale in days)					

30

35

Composition	D14	D28	D42	D56	D90	D180
Composition (W)	nd	nd	nd	nd	nd	nd
Composition (X)	100	100	1000	1000	1000	nd
Composition (Y)	100	100	1000	1000	1000	nd
Composition (Z)	100	100	1000	1000	3000	nd
Control C1	100	100	8000	3000	8000	nd
Control C2	100	100	1000	1000	1000	nd

WHAT IS CLAIMED IS:

1. A composition comprising an aqueous solution comprising:

(i) at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence, and

5 (ii) as an adjuvant of immunity, a surfactant, or a mixture of

surfactants, having an overall HLB number of between 5 and 15.

10 2. The composition as defined in Claim 1, in which the surfactant or mixture of surfactants comprise modified fatty substances.

15 3. The composition as defined in Claim 2, in which the surfactant or mixture of surfactants comprise modified fatty substances having an overall HLB number of between 6 and 14.

20 4. The composition as defined in Claim 2, in which the modified fatty substance is an alkoxylated derivative of an oil or an alkoxylated derivative of an alkyl ester of an oil.

25 5. The composition as defined in Claim 4, in which the modified fatty substance is an ethoxylated derivative of an oil having a number of EOs of between 1 and 60.

6. The composition as defined in Claim 3, in which the modified fatty substance is an alkoxylated derivative of corn oil, or a mixture of alkoxylated derivatives of corn oil, having an overall HLB number of between 10 and 14.

25 7. The composition as defined in Claim 3, in which the modified fatty substance is an ethoxylated derivative of castor oil, or a mixture of alkoxylated derivatives of castor oil, having an overall HLB of between 7 and 10.

30 8. The composition as defined in Claim 6, in which the modified fatty substance is an ethoxylated derivative of corn oil having a number of EOs of

between 20 and 40.

9. The composition as defined in Claim 7, in which the modified fatty substance is a mixture of ethoxylated derivatives of castor oil having a number of 5 EO's equal to 7, and of ethoxylated derivatives of castor oil having a number of EO's equal to 60.

10. The composition as defined in Claim 1, in which the surfactant or mixture of surfactants comprise an alkoxylated derivative of an ester of a fatty acid and of a polyol or the alkoxylated derivative of an ether of a fatty alcohol and of a polyol

15. The composition as defined in Claim 1, in which the surfactant or mixture of surfactants comprise an ethoxylated derivative of an ester of a fatty acid and of a polyol, or the ethoxylated derivative of an ether of a fatty alcohol and of a polyol, having a number of EO's of between 1 and 60.

20. The composition as defined in Claim 10, in which the surfactant, or the mixture of surfactants, has an overall HLB number of between 10 and 14.

25. The composition as defined in Claim 11, in which the surfactant is an ethoxylated derivative of mannan oleate having a number of EO's of between 5 and 15.

14. The composition as defined in Claim 1, further comprising an immunostimulant.

25. The composition as defined in Claim 1, further comprising one or more water-soluble metal cation organic salts.

30. The composition as defined in Claim 1, further comprising a sympathomimetic compound comprising a catecholamine, an amphetamine, a phenylisopropylamine or a tyramine.

17. The composition as defined in Claim 1, in a form suitable for administration of said at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence to a human or an animal.

5 18. A medicinal product comprising the composition according to Claim 17, wherein said at least one antigen or said at least one in vivo generator of a compound comprising an amino acid sequence is present in said composition in an amount effective for treating or for preventing infectious and/or functional diseases.

10 19. A method of providing an adjuvant effect to a vaccine comprising at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence comprising combining said antigen or in vivo generator with a surfactant or with a mixture of surfactants, said surfactant or mixture of surfactants having an overall HLB number of between 5 and 15.

15 20. A method of providing an adjuvant effect to a vaccine as defined in Claim 19, wherein said vaccine does not include an oily phase.

20 21. The composition as defined in Claim 10, wherein said alkoxylate derivative is an alkoxylated fatty acid triglyceride, a polyglycerol alkoxylated ester of a fatty acid, an alkoxylated ester of a fatty acid with a hexol or the alkoxylated ester of a fatty acid with a hexol anhydride.

25 22. The composition as defined in Claim 21, wherein said hexol is sorbitol or mannitol.

23. The composition as defined in Claim 22, wherein said hexol anhydride is sorbitan or mannan.

30 24. The composition as defined in Claim 10, wherein the surfactant or mixture of surfactants has an overall HLB number of between 12 and 13.5.

25. The composition as defined in Claim 13, in which the number of EO_s is between 7 and 11.

26. The composition as defined in Claim 14, wherein said immunostimulant
5 is AVRIDINE®, an MDP derivative, a mycolic acid derivative or a lipid A derivative.

27. The composition as defined in Claim 15, wherein said water-soluble metal cation organic salt is calcium gluconate, manganese gluconate, aluminum salicylate or soluble aluminum acetate.

28. The composition as defined in Claim 16, wherein said sympathomimetic compound is ephedrine, isoproterenol, L-Epinephrine, levarterenol, phenylephedrine, or salbutamol.

29. The medicinal product as defined in Claim 18, wherein said disease is one engendered by a virus, a microorganism or a parasite.

30. The method as defined in Claim 19, wherein said vaccine is suitable for a mucosal vaccination.

31. The method as defined in Claim 30, wherein said vaccine is suitable for application orally, nasally, rectally or vaginally.

ABSTRACT OF THE DISCLOSURE

A composition comprising an aqueous solution comprising:

(i) at least one antigen or at least one in vivo generator of a compound

comprising an amino acid sequence, and

5 (ii) as an adjuvant of immunity, a surfactant, or a mixture of

surfactants, having an overall HLB number of between 5 and 15.